The role of nucleoside transport in the antineoplastic activity of purine hucleoside chemotherapeutic agents

Current Cancer Therapy Reviews

Volumn 4, Issue 1, 2008, Pages 21-30

  King, Karen M ^a,b   Cass, Carol E ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

Anti cancer purine nucleoside analogues; Nucleoside transporters

Indexed keywords

8 CHLOROADENOSINE; ADENINE DERIVATIVE; CARRIER PROTEIN; CLADRIBINE; CLOFARABINE; FLUDARABINE; FORODESINE; GUANINE ARABINOSIDE; NELARABINE; NUCLEOSIDE TRANSPORTER; PENTOSTATIN; PURINE NUCLEOSIDE DERIVATIVE;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DIFFUSION; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; HUMAN; INFECTION; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

EID: 49349096364     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339408783565501     Document Type: Review

References (136)

1. Adams A, Harkness RA. Adenosine deaminase activity in thymus and other human tissues. Clin Exp Immunol 1976; 26: 647-9.
2. O Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, Cheson BD, Hoth DF. 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug. Ann Intern Med 1988; 108: 733-43.
3. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2: 1067-9.
4. Cohen A, Hirschhorn R, Horowitz SD, et al. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A 1978; 75: 472-6.
5. Coleman MS, Donofrio J, Hutton JJ, et al. Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency. J Biol Chem 1978; 253: 1619-26.
6. Donofrio J, Coleman MS, Hutton JJ, Daoud A, Lampkin B, Dyminski J. Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease. J Clin Invest 1978; 62: 884-7.
7. Woo PW, Dion HW, Lange SM, Dahl LF, Durham LJ. A novel adenosine and araA deaminase inhibitor, (R)-3-(2-deoxy-B-Derythropento- furanosyl)-3,6,7,8-tetrahydroimidazo (4,5-d) (1.3) diazepin- 8-ol. J Heterocycl Chem 1974; 11: 64.
8. Poplack DG, Sallan SE, Rivera G, et al. Phase I study of 2′- deoxycoformycin in acute lymphoblastic leukemia. Cancer Res 1981; 41: 3343-6.
9. Grever MR, Siaw MF, Jacob WF, et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981; 57: 406-17.
10. Grever MR, Leiby JM, Kraut EH, et al. Low dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985; 3: 1196-201.
11. Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989; 7: 168-72.
12. Thaler J, Grunewald K, Gattringer C, et al. Long term follow up of patients with hairy cell leukaemia treated with pentostatin lymphocyte subpopulations and residual bone marrow infiltration. Br J Haematol 1993; 84: 75-82.
13. Spiers AS, Moore D, Cassileth PA, et al. Remissions in hairy cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 1987; 316: 825-30.
14. Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D. Long term follow up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol 1999; 106: 515-9.
15. Ribeiro P, Bouaffia F, Peaud PY, et al. Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 1999; 85: 65-71.
16. Rafel M, Cervantes F, Beltran JM, et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia results of a Spanish collaborative study of 80 patients. Cancer 2000; 88: 352-7.
17. Johnston JB, Eisenhauer E, Wainman N, Corbett WE, Zaentz SD, Daeninck PJ. Long term outcome following treatment of hairy cell leukemia with pentostatin (Nipent) a National Cancer Institute of Canada study. Semin Oncol 2000; 27: 32-6.
18. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A 1980; 77: 6865-9.
19. Christensen LF, Broom AD, Robins MJ, Bloch A. Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy- -and- -Derythro- pentofuranosyl)purines. J Med Chem 1972; 15: 735-9.
20. Saven A, Piro L. Newer purine analogues for the treatment of hairy cell leukemia. N Engl J Med 1994; 330: 691-7.
21. Saven A, Piro LD. 2-Chlorodeoxyadenosine a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994; 120: 784-91.
22. Piro LD. Cladribine in the treatment of low grade non-Hodgkin's lymphoma. Semin Hematol 1996; 33: 34-9.
23. Hoffman MA. Cladribine for the treatment of indolent non Hodgkin's lymphomas. Semin Hematol 1996; 33: 40-4.
24. Tallman MS, Hakimian D. Purine nucleoside analogs emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463-74.
25. Beutler E, Sipe J, Romine J, McMillan R, Zyroff J, Koziol J. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin Hematol 1996; 33: 45-52.
26. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13.
27. Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 1984; 81: 2232-6.
28. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2- chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737-43.
29. Wang L, Karlsson A, Arner ES, Eriksson S. Substrate specificity of mitochondrial 2'-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. J Biol Chem 1993; 268: 22847-52.
30. Hentosh P, Koob R, Blakley RL. Incorporation of 2-halogeno-2′- deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta. J Biol Chem 1990; 265: 4033-40.
31. Hentosh P, McCastlain JC, Blakley RL. Effects of 2-chloro-2′- deoxyadenosine 5′-triphosphate on DNA synthesis in vitro by purified bacterial and viral DNA polymerases. Biochemistry 1991; 30: 547-54.
32. Hirota Y, Yoshioka A, Tanaka S, et al. Imbalance of deoxyribonucleoside triphosphates DNA double-strand breaks and cell death caused by 2-chlorodeoxyadenosine in mouse FM3A cells. Cancer Res 1989; 49: 915-9.
33. Huang P, Plunkett W. Fludarabine and gemcitabine induced apoptosis incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995; 36: 181-8.
34. Kuwabara M, Tanabe K, Hiraoka W, et al. 2-Chlorodeoxyadenosine inhibits the repair of DNA double strand breaks and does not inhibit the repair of DNA single strand breaks in X irradiated Chinese hamster V79 cells. Chem Biol Interact 1991; 79: 349-58.
35. Pettitt AR, Sherrington PD, Cawley JC. Role of poly(ADPribosyl) ation in the killing of chronic lymphocytic leukemia cells by purine analogues. Cancer Res 2000; 60: 4187-93.
36. Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989; 49: 6923-8.
37. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985; 75: 377-83.
38. Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′- deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143-50.
39. Robak T. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies. Transfus Apher Sci 2005; 32: 33-44.
40. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537-43.
41. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005-37.
42. Ross SR, McTavish D, Faulds D. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs 1993; 45: 737-59.
43. Robak T. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues facts and controversies. Drugs Aging 2005; 22: 983-1012.
44. Malspeis L, Grever MR, Staubus AE, Young D. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Semin Oncol 1990; 17: 18-32.
45. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues mechanisms of drug resistance and reversal strategies. Leukemia 2001; 15: 875-90.
46. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol 1990; 17: 3-17.
47. Huang P, Plunkett W. Action of 9-beta-D-arabinofuranosyl-2- fluoroadenine on RNA metabolism. Mol Pharmacol 1991; 39: 449-55.
48. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2'-deoxyadenosine. Proc Natl Acad Sci U S A 1992; 89: 2970-4.
49. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2- deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res 1991; 51: 2386-94.
50. Parker WB, Shaddix SC, Rose LM, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-beta- D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro- beta- D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluorobeta- D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol 1999; 55: 515-20.
51. Waud WR, Schmid SM, Montgomery JA, Secrist JA, 3rd. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-Darabinofuranosyl) adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 2000; 19: 447-60.
52. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379-86.
53. Jeha S, Gandhi V, Chan KW, et al. Clofarabine a novel nucleoside analog is active in pediatric patients with advanced leukemia. Blood 2004; 103: 784-9.
54. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM, Secrist JA, 3rd. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. J Med Chem 1992; 35: 397-401.
55. Qian M, Wang X, Shanmuganathan K, Chu CK, Gallo JM. Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluorobeta- D-arabinofuranosyl)adenine in rats. Cancer Chemother Pharmacol 1994; 33: 484-8.
56. Takahashi T, Kanazawa J, Akinaga S, Tamaoki T, Okabe M. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine a novel deoxyadenosine analog against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol 1999; 43: 233-40.
57. Lotfi K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2′-deoxyadenosine a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999; 5: 2438-44.
58. Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy- 2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res 1996; 56: 3030-7.
59. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2- deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995; 55: 2847-52.
60. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4- hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 3580-9.
61. Reist EJ, Goodman L. Synthesis of 9-Beta-D-Arabinofuranosylguanine. Biochemistry 1964; 3: 15-8.
62. Giblett ER, Ammann AJ, Wara DW, Sandman R, Diamond LK. Nucleoside-phosphorylase deficiency in a child with severely defective T cell immunity and normal B cell immunity. Lancet 1975; 1: 1010-3.
63. Scharenberg JG, Spaapen LJ, Rijkers GT, Wadman SK, Staal GE, Zegers BJ. Mechanisms of deoxyguanosine toxicity for human T and B lymphocytes. Adv Exp Med Biol 1986; 195(Pt B): 191-9.
64. Mitchell BS, Mejias E, Daddona PE, Kelley WN. Purinogenic immunodeficiency diseases selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A 1978; 75: 5011-4.
65. Montgomery JA. Purine nucleoside phosphorylase a target for drug design. Med Res Rev 1993; 13: 209-28.
66. Ullman B, Martin DW, Jr. Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts. J Clin Invest 1984; 74: 951-5.
67. Cohen A, Lee JW, Gelfand EW. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood 1983; 61: 660-6.
68. Shewach DS, Daddona PE, Ashcraft E, Mitchell BS. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res 1985; 45: 1008-14.
69. Lambe CU, Averett DR, Paff MT, Reardon JE, Wilson JG, Krenitsky TA. 2-Amino-6-methoxypurine arabinoside an agent for T-cell malignancies. Cancer Res 1995; 55: 3352-6.
70. Krenitsky TA, Tuttle JV, Koszalka GW, et al. Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J Biol Chem 1976; 251: 4055-61.
71. Lewis RA, Link L. Phosphorylation of arabinosyl guanine by a mitochondrial enzyme of bovine liver. Biochem Pharmacol 1989; 38: 2001-6.
72. Rodriguez CO, Jr, Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 2002; 62: 3100-5.
73. Averett DR, Koszalka GW, Fyfe JA, Roberts GB, Purifoy DJ, Krenitsky TA. 6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella zoster virus. Antimicrob Agents Chemother 1991; 35: 851-7.
74. Parker WB, Secrist JA, 3rd, Waud WR. Purine nucleoside antimetabolites in development for the treatment of cancer. Curr Opin Investig Drugs 2004; 5: 592-6.
75. Kicska GA, Long L, Horig H, et al. Immucillin H a powerful transition state analog inhibitor of purine nucleoside phosphorylase selectively inhibits human T lymphocytes. Proc Natl Acad Sci U S A 2001; 98: 4593-8.
76. Bantia S, Ananth SL, Parker CD, Horn LL, Upshaw R. Mechanism of inhibition of T acute lymphoblastic leukemia cells by PNP inhibitor BCX 1777. Int Immunopharmacol 2003; 3: 879-87.
77. Schramm VL. Development of transition state analogues of purine nucleoside phosphorylase as anti T cell agents. Biochim Biophys Acta 2002; 1587: 107-17.
78. Gandhi V, Kilpatrick JM, Plunkett W, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 2005; 106: 4253-60.
79. Ally S, Clair T, Katsaros D, et al. Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site selective 8-Cl-cyclic adenosine monophosphate. Cancer Res 1989; 49: 5650-5.
80. Taylor CW, Yeoman LC. Inhibition of colon tumor cell growth by 8-chloro-cAMP is dependent upon its conversion to 8-chloroadenosine. Anticancer Drugs 1992; 3: 485-91.
81. Cummings J, Langdon SP, Ritchie AA, et al. Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'- monophosphate in breast cancer patients and xenograft bearing mice. Ann Oncol 1996; 7: 291-6.
82. Gandhi V, Ayres M, Halgren RG, Krett NL, Newman RA, Rosen ST. 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res 2001; 61: 5474-9.
83. Stellrecht CM, Rodriguez CO, Jr, Ayres M, Gandhi V. RNA directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res 2003; 63: 7968-74.
84. Cass CE. Nucleoside Transport. In Georgopapadakou NH, editor. Drug Transport in Antimicrobial and Anticancer Chemotherapy. New York, NY: Marcel Deker, 1995; pp. 403-51.
85. Griffiths M, Yao SY, Abidi F, et al. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J 1997; 328 (Pt 3): 739-43.
86. Baldwin SA, Yao SY, Hyde RJ, et al. Functional characterisation of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 2005; 280: 15880-87.
87. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447: 735-43.
88. Griffiths M, Beaumont N, Yao SY, et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 1997; 3: 89-93.
89. Crawford CR, Patel DH, Naeve C, Belt JA. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J Biol Chem 1998; 273: 5288-93.
90. Yao SY, Ng AM, Vickers MF, et al. Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation. J Biol Chem 2002; 277: 24938-48.
91. Visser F, Baldwin SA, Isaac RE, Young JD, Cass CE. Identification and mutational analysis of amino acid residues involved in dipyridamole interactions with human and Caenorhabditis elegans equilibrative nucleoside transporters. J Biol Chem 2005; 280: 11025-34.
92. Visser F, Vickers MF, Ng AM, Baldwin SA, Young JD, Cass CE. Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J Biol Chem 2002; 277: 395-401.
93. Pisoni RL, Thoene JG. The transport systems of mammalian lysosomes. Biochim Biophys Acta 1991; 1071: 351-73.
94. Lai Y, Tse CM, Unadkat JD. Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 2004; 279: 4490-7.
95. Mani RS, Hammond JR, Marjan JM, et al. Demonstration of equilibrative nucleoside transporters (hENT1 and hENT2) in nuclear envelopes of cultured human choriocarcinoma (BeWo) cells by functional reconstitution in proteoliposomes. J Biol Chem 1998; 273: 30818-25.
96. Barnes K, Dobrzynski H, Foppolo S, et al. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res 2006; 99: 510-9.
97. Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 2004; 279: 50042-9.
98. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1996; 1286: 153-81.
99. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 2001; 280: 951-9.
100. Jennings LL, Hao C, Cabrita MA, et al. Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology 2001; 40: 722-31.
101. Ritzel MW, Ng AM, Yao SY, et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 2001; 276: 2914-27.
102. Ritzel MW, Yao SY, Huang MY, Elliott JF, Cass CE, Young JD. Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am J Physiol 1997; 272: C707-14.
103. Ritzel MW, Yao SY, Ng AM, Mackey JR, Cass CE, Young JD. Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol 1998; 15: 203-11.
104. Smith KM, Slugoski MD, Loewen SK, et al. The broadly selective human Na+/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics. J Biol Chem 2005; 280: 25436-49.
105. Mackey JR, Galmarini CM, Graham KA, et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood 2005; 105: 767-74.
106. Cass CE, Young JD, Baldwin SA, et al. Nucleoside transporters of mammalian cells. Pharm Biotechnol 1999; 12: 313-52.
107. Paterson AR, Gati WP, Vijayalakshmi D, et al. Proc Am Assoc Cancer Res 1993; 34: A84.
108. Flanagan SA, Meckling-Gill KA. Characterization of a novel Na+-dependent, guanosine-specific, nitrobenzylthioinosine-sensitive transporter in acute promyelocytic leukemia cells. J Biol Chem 1997; 272: 18026-32.
109. Gutierrez MM, Brett CM, Ott RJ, Hui AC, Giacomini KM. Nucleoside transport in brush border membrane vesicles from human kidney. Biochim Biophys Acta 1992; 1105: 1-9.
110. Gutierrez MM, Giacomini KM. Substrate selectivity, potential sensitivity and stoichiometry of Na(+)-nucleoside transport in brush border membrane vesicles from human kidney. Biochim Biophys Acta 1993; 1149: 202-8.
111. Gutierrez MM, Giacomini KM. Expression of a human renal sodium nucleoside cotransporter in Xenopus laevis oocytes. Biochem Pharmacol 1994; 48: 2251-3.
112. Huang QQ, Yao SY, Ritzel MW, Paterson AR, Cass CE, Young JD. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. J Biol Chem 1994; 269: 17757-60.
113. Yao SY, Ng AM, Muzyka WR, et al. Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)- sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. J Biol Chem 1997; 272: 28423-30.
114. Yao SY, Cass CE, Young JD. Transport of the antiviral nucleoside analogs 3′-azido-3′-deoxythymidine and 2′,3′-dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes. Mol Pharmacol 1996; 50: 388-93.
115. Che M, Ortiz DF, Arias IM. Primary structure and functional expression of a cDNA encoding the bile canalicular, purine-specific Na(+)-nucleoside cotransporter. J Biol Chem 1995; 270: 13596-9.
116. Handa M, Choi DS, Caldeiro RM, Messing RO, Gordon AS, Diamond I. Cloning of a novel isoform of the mouse NBMPRsensitive equilibrative nucleoside transporter (ENT1) lacking a putative phosphorylation site. Gene 2001; 262: 301-7.
117. Gerstin KM, Dresser MJ, Wang J, Giacomini KM. Molecular cloning of a Na+-dependent nucleoside transporter from rabbit intestine. Pharm Res 2000; 17: 906-10.
118. Wu SK, Ann DK, Kim KJ, Lee VH. Fine tuning of rabbit equilibrative nucleoside transporter activity by an alternatively spliced variant. J Drug Target 2005; 13: 521-33.
119. Kiss A, Farah K, Kim J, Garriock RJ, Drysdale TA, Hammond JR. Molecular cloning and functional characterization of inhibitorsensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain. Biochem J 2000; 352 (Pt 2): 363-72.
120. Anderson CM, Xiong W, Young JD, Cass CE, Parkinson FE. Demonstration of the existence of mRNAs encoding N1/cif and N2/cit sodium/nucleoside cotransporters in rat brain. Brain Res Mol Brain Res 1996; 42: 358-61.
121. Chen SF, Stoeckler JD, Parks RE, Jr. Transport of deoxycoformycin in human erythrocytes. Measurement by adenosine deaminase titration and radioisotope assays. Biochem Pharmacol 1984; 33: 4069-79.
122. Wiley JS, Smith CL, Jamieson GP. Transport of 2′-deoxycoformycin in human leukemic and lymphoma cells. Biochem Pharmacol 1991; 42: 708-10.
123. Avery TL, Rehg JE, Lumm WC, Harwood FC, Santana VM, Blakley RL. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res 1989; 49: 4972-8.
124. Gati WP, Paterson ARP, Belch AR, et al. Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine. Leuk Lymphoma 1998; 32: 45-54.
125. Molina-Arcas M, Bellosillo B, Casado FJ, et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 2003; 101: 2328-34.
126. King KM, Cass CE. Membrane Transport of 2-chloro-2′- deoxyadenosine and 2-chloro-2′-arabinofluoro-2′-deoxyadenosine is required for cytotoxicity. Proc Am Assoc Cancer Res 1994; 35: A3436.
127. Lang TT, Young JD, Cass CE. Interactions of nucleoside analogs, caffeine, and nicotine with human concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line. Mol Pharmacol 2004; 65: 925-33.
128. Gerstin KM, Dresser MJ, Giacomini KM. Specificity of human and rat orthologs of the concentrative nucleoside transporter, SPNT. Am J Physiol Renal Physiol 2002; 283: F344-9.
129. Schaner ME, Wang J, Zevin S, Gerstin KM, Giacomini KM. Transient expression of a purine-selective nucleoside transporter (SPNTint) in a human cell line (HeLa). Pharm Res 1997; 14: 1316-21.
130. King KM, Damaraju VL, Vickers MF, et al. A comparison of the transportability and its role in cytotoxicity of clofarabine, cladribine and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 2006; 69: 346-53.
131. Schaner ME, Wang J, Zhang L, Su SF, Gerstin KM, Giacomini KM. Functional characterization of a human purine-selective, Na+- dependent nucleoside transporter (hSPNT1) in a mammalian expression system. J Pharmacol Exp Ther 1999; 289: 1487-91.
132. Owen RP, Badagnani I, Giacomini KM. Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2. J Biol Chem 2006; 281: 26675-82.
133. Crawford CR, Ng CY, Ullman B, Belt JA. Identification and reconstitution of the nucleoside transporter of CEM human leukemia cells. Biochim Biophys Acta 1990; 1024: 289-97.
134. Lang TT, Selner M, Young JD, Cass CE. Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drugresistant leukemia cells. Mol Pharmacol 2001; 60: 1143-52.
135. Prus KL, Averett DR, Zimmerman TP. Transport and metabolism of 9-beta-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res 1990; 50: 1817-21.
136. Flanagan SA, Gandhi V, Secrist JA, 3rd, Meckling KA. The novel nucleoside transport system exhibited by NB4 cells, csg, transports deoxyguanosine analogues, including ara-G. Biochem Pharmacol 2003; 66: 733-7.